Safety of statins

Current Opinion in Lipidology

Volumn 19, Issue 6, 2008, Pages 558-562

  Brown, William Virgil ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Liver dysfunction; Proteinuria and neuropathy; Rhabdomyolysis; Statin

Indexed keywords

AMIODARONE; ANTIFUNGAL AGENT; ATORVASTATIN; CALCIUM CHANNEL BLOCKING AGENT; CERIVASTATIN; CYCLOSPORIN; EZETIMIBE; FENOFIBRATE; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; MACROLIDE; MEVALONIC ACID; MEVINOLIN; PHENYTOIN; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; UBIQUINONE; WARFARIN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIARY TRACT DISEASE; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COGNITIVE DEFECT; CREATININE BLOOD LEVEL; DEMENTIA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG EXCRETION; DRUG FATALITY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; HUMAN; HYPERCHOLESTEROLEMIA; LIPOPROTEIN BLOOD LEVEL; LIVER FAILURE; MONOTHERAPY; MUSCLE INJURY; MYALGIA; MYOPATHY; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROTEINURIA; REVIEW; RHABDOMYOLYSIS; SIDE EFFECT; STROKE; TRANSIENT ISCHEMIC ATTACK;

BIOCHEMICAL PHENOMENA; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KIDNEY; LIVER; NEURONS;

EID: 56549100353     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOL.0b013e328319baba     Document Type: Review

References (38)

1. Thavendiranathan P, Bagai A, Brookhart MA, Choudhry NK. Primary prevention of cardiovascular diseases with statin therapy: a meta-analysis of randomized controlled trials. Arch Internal Med 2006; 166:2307-2313.
2. Chan PS, Nallamothu BK, Gurm HS, et al. Incremental benefit and cost-effectiveness of high-dose statin therapy in high-risk patients with coronary artery disease. Circulation 2007; 115:2398-2409.
3. Brown M, Goldstein J. Sterol regulatory element binding proteins (SREBPs): controllers of lipid synthesis and cellular uptake. Nutr Rev 1998; 56:S1-S6.
4. Vaughan CJ, Gotto AM Jr. Update on statins: 2003. Circulation 2004; 110:886-892.
5. Young JM, Florkowski CM, Molyneux SL, et al. Effect of coenzyme Q(10) supplementation on simvastatin-induced myalgia. Am J Cardiol 2007; 100:1400-1403.
6. Berthold HK, Naini A, Di Mauro S, et al. Effect of eztimibe and/or simvastatin on coenzyme Q10 levels in plasma: a randomized trial. Drug Saf 2006; 29:703-712.
7. Pacanowski MA, Frye RF, Osatohanmen E, et al. Plasma coenzyme Q10 predicts lipid-lowering response to high-dose atorvastatin. J Clin Lipid 2008; 2:289-297.
8. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke systematic review and meta-analysis. BMJ 2003; 326:1423-1430.
9. Black C, Jick H. Etiology and frequency of rhabdomyolysis. Pharmacotherapy 2002; 22:1524-1526.
10. Graham DJ, Staffa JA, Shatin D, et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 2004; 292:2585-2590.
11. Law M, Rudnicka AR. Statin safety: a systematic review. Am J Cardiol 2006; 97 (Suppl 8A):52C-60C.
12. Pedersen TR, Faergeman O, Kastelein JJP, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 2005; 294:2437-2445.
13. SEARCH Study Collaborative Group. Study of the effectiveness of additional reductions in cholesterol and homocysteine (SEARCH): characteristics of a randomized trial among 12064 myocardial infarction survivors. Am Heart J 2007; 154:815-823.
14. Thompson PD, Zmuda JM, Domalik LJ, et al. Lovastatin increases exercise-induced skeletal muscle injury. Metabolism 1997; 46:1206-1210.
15. Clarkson PM, Hubal MJ. Exercise-induced muscle damage in humans. Am J Phys Med Rehabil 2002; 81:S52-S69.
16. Mulder AB, van Liif HJ, Bon MA, et al. Association of polymorphism in the cytochrome CYP2D6 and the efficacy and tolerability of simvastatin. Clin Pharmacol Ther 2001; 70:546-551.
17. Fiegenbaum M, da Silveira FR, Van der Sand CR, et al. The role of common variants of ABCA1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and tolerability of simvastatin. Clin Pharmacol Ther 2005; 78:551-558.
18. The SEARCH Collaborative Group. SLCO1B1 variants and statin-induced myopathy: a genomewide study. 2008; 359:789-799.
19. Bays H. Statin safety an overview and assessment of the data: 2005. Am J Cardiol 2006; 97 (Suppl 8A):6C-26C.
20. Bottorf MB. Statin safety and drug interactions: clinical implications. Am J Cardiol 2006; 97 (Suppl 8A):6C-26C.
21. Prueksaritanont T, Zhao JJ, Ma B, et al. Mechanistic studies on metabolic interactions between gemfibrozil and statins. J Pharmacol Exp Ther 2002; 301:1042-1051.
22. Davidson MH, Armani A, McKenney JM, Jacobson TA. Safety considerations with fibrate therapy. Am J Cardiol 2007; 99 (Suppl 1):3C-18C.
23. Heart Protection Study Collaborative Group, Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20,536 people with cerebrovascular disease or other high-risk conditions. Lancet 2004; 363:757-767.
24. Heart Protection Study Collaborative Group, MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals a randomised placebo-controlled trial. Lancet 2002; 360:7-22.
25. Cohen DE, Anania FA, Chalasani N. An assessment of statin safety by hepatologists. Am J Cardiol 2006; 97 (Suppl 8A):77C-81C.
26. Kinnman N, Hultcrantz R. Lipid lowering medication and hepatotoxicity. J Intern Med 2001; 250:183-185.
27. Tolman KG. The liver and lovastatin. Am J Cardiol 2002; 89:1374-1380.
28. Jacobson TA. Statin safety lessons from new drug applications for marketed statins. Am J Cardiol 2006; 97 (Suppl 8A):44C-51C.
29. Verhulst A, D'Haese PC, De Broe ME. Inhibitors of HMG-CoA reductase reduce receptor-mediated endocytosis in human kidney proximal tubular cells. J Am Soc Nephrol 2004; 15:2249-2257.
30. Sidaway E, Davidson RG, McTaggart F, et al. Inhibitors of 3-hydroxy-3-methylglutaryl-CoA reductase reduce receptor-mediated endocytosis in opossum kidney cells. J Am Soc Nephrol 2004; 15:2258-2265.
31. Stein EA, Marais DA, Ducobu J, et al. Comparison of short-term renal effects and efficacy of rosuvastatin 40 mg and simvastatin 80 mg, followed by assessment of long-term renal effects of rosuvastatin 40 mg, in patients with dyslipidemia. J Clin Lipidol 2007; 1:287-299.
32. Bianchi R, Bigazzi A, Caiazza VM, Campese A. controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. Am J Kidney Dis 2003; 41:565-570.
33. Fried LF, Orchard TJ, Kasiske BL, Lipids Renal Disease Progression Meta-Analysis Study Group. Effect of lipid reduction on the progression of renal disease a meta-analysis. Kidney Int 2001; 59:260-269.
34. Fellstrom B, Holdaas H, Jardine AG, et al., and other Assessment of Lescol in Renal Transplantation Study Investigators. Effect of fluvastatin on renal end points in the Assessment of Lescol in Renal Transplant (ALERT) trial. Kidney Int 2004; 66:1549-1555.
35. Brass LM, Alberts MJ, Sparks L. An assessment of statin safety by neurologists. Am J Cardiol 2006; 97 (Suppl 8A):86C-88C.
36. Chong PH, Boskovich A, Stevkovic N, Bartt RE. Statin-associated peripheral neuropathy review of literature. Pharmacotherapy 2004; 24:1194-1203.
37. PROspective Study of Pravastatin in the Elderly at Risk (PROSPER) Study Group, Pravastatin in elderly individuals at risk of vascular disease (PROSPER) a randomised controlled trial. Lancet 2002; 360:1623-1630.
38. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006; 355:549-559.